Biosynex SA (EPA:ALBIO)

Market Cap	14.89M -47.8%
Revenue (ttm)	97.95M -5.9%
Net Income	-70.99M
EPS	-4.82
Shares Out	18.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	590
Average Volume	5,712
Open	0.8200
Previous Close	0.7940
Day's Range	0.8000 - 0.8200
52-Week Range	0.4550 - 1.7300
Beta	0.79
RSI	41.29
Earnings Date	Apr 30, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products. The company was founded in 1993 and is based in Illkirch-Graf...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1993
• Employees: 454
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALBIO

Financial Performance

In 2024, Biosynex's revenue was 101.17 million, an increase of 8.81% compared to the previous year's 92.98 million. Losses were -43.33 million, 17.3% more than in 2023.